Effects of antagonists of glutamate receptors on pro-inflammatory cytokines in the brain cortex of rats subjected to experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 261, Issue 1-2, 2013, Pages 67-76

  Sulkowski, Grzegorz ^a   Dabrowska Bouta, Beata ^a   Chalimoniuk, Małgorzata ^a,b   Struzyńska, Lidia ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b CARDINAL STEFAN WYSZY SKI UNIVERSITY   (Poland)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis (EAE); Glutamate receptors antagonists; Inflammation

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 CARBOXY 2 METHYLPHENYLGLYCINE; AMANTADINE; CYCLOOXYGENASE 2; CYTOKINE; FRACTALKINE; GLUTAMATE RECEPTOR ANTAGONIST; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 3; MEMANTINE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

CYTOKINES; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE); GLUTAMATE RECEPTORS ANTAGONISTS; INFLAMMATION;

AMANTADINE; ANIMALS; CEREBRAL CORTEX; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GUINEA PIGS; INFLAMMATION MEDIATORS; MEMANTINE; RATS; RATS, INBRED LEW; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 84880829587     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.05.006     Document Type: Article

References (61)

1. Ambrosini E., Columba-Cabezas S., Serafini B., Musccella A., Alsoisi F. Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia 2003, 41:290-300.
2. Besong G., Battaglia G., D'Onofrio M., Di Marco R., Ngomba R.T., Storto M., et al. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J. Neurosci. 2002, 22:5403-5411.
3. Biber K., Laurie D.J., Berthele A., Sommer B., Tolle T.R., Gebicke-Harter P.J., van Calker D., Boddeke H.W.G.M. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 1999, 72:1671-1680.
4. Bolton C., Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J. Pharmacol. Exp. Ther. 1997, 282:397-402.
5. Bolton C., Paul C. Glutamate receptors in neuroinflammatory demyelinating disease. Mediat. Inflamm. 2006, 2006:1-12.
6. Bordli F., Ugolini A. Group I metabotropic glutamate receptors: implication for brain diseases. Prog. Neurobiol. 1999, 59:55-79.
7. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 1998, 18:9594-9600.
8. Bruno V., Battaglia G., Casabona G., Copani A., Caciagli F., Nicoletti F. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J. Cereb. Blood Flow Metab. 2001, 21:1013-1033.
9. Campbell I.L., Stalder A.K., Akawa Y., Pagenstecher A., Asensio V.C. Transgenic models to study the actions of cytokines in the central nervous system. Neuroimmunomodulation 1998, 5:126-135.
10. Cartmell J., Schoepep D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 2000, 75:1611-1626.
11. Centonze D., Muzio L., Rossi S., Furlan R., Bernardi G., Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010, 17:1083-1091.
12. Chen H.S.V., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 2006, 97:1611-1626.
13. Chen H.S., Pellergini J.W., Aggarwal S.K., Lei S.Z., Warach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 1992, 12:4427-4436.
14. Choi D.W. Calcium and excitotoxic neuronal injury. Ann. N. Y. Acad. Sci. 1994, 747:162-171.
15. Chomczyński P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
16. Clark A.K., Malcangio M. Microglia signaling mechanisms: cathepsin S and fractalkine. Exp. Neurol. 2012, 234:283-292.
17. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
18. Cuzner M.L., Hayes G.M., Newcombe J., Wooroofe M.N. The nature of inflammatory components during demyelination in multiple sclerosis. J. Neuroimmunol. 1998, 20:203-209.
19. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 1997, 21:455-468.
20. Downen M., Amaral T.D., Hua L.L., Zhao M.L., Lee S.C. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999, 28:114-127.
21. Faden A.I., O'Leary D.M., Fan L., Bao W., Mullins P.G., Movsesyan V.A. Selective blockade of mGluR 1 receptor reduces traumatic neuronal injury in vitro and improves outcome after brain trauma. Exp. Neurol. 2001, 167:435-444.
22. Geurts J.J.G., Wolswijk G., Bö L., Van der Valk P., Polman C.H., Troost D., Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003, 126:1755-1766.
23. Glabinski A.R., Tuohy V.K., Ransohoff R.M. Expression of chemokines RANTES, MIP-1 alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998, 5:166-171.
24. Groom A.J., Smith T., Turski L. Multiple sclerosis and glutamate. Ann. N. Y. Acad. Sci. 2003, 993:229-275.
25. Ikonomidou C., Turski L. Prevention of trauma-induced neurodegeneration in infant and adult rat brain: glutamate antagonists. Metab. Brain Dis. 1996, 11:125-141.
26. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
27. Joseph E.K., Levine J.D. Caspase signaling in neuropathic and inflammatory pain in the rat. Eur. J. Neurosci. 2004, 20:2896-2902.
28. Kanwar J.R. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem. 2005, 12:2947-2962.
29. Kanwar J.R., Kanwar R.K., Krisannsen G.W. Simultaneous neuroprotection and blockade of inflammation reverse autoimmune encephalomyelitis. Brain 2004, 127:1313-1331.
30. Kerschensteiner M., Stadelmann C., Buddeberg B.S., Merkler D., Bareyre F.M., Anthony D.C., Linington C., Brück W., Schwab M.E. Animal model - targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am. J. Pathol. 2004, 164:1455-1469.
31. Laemmli V.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1976, 227:680-685.
32. Lassmann H. Mechanism of demyelination and tissue destruction in multiple sclerosis. Clin. Neurol. Neurosurg. 2002, 104:168-171.
33. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
34. Lowry O.W., Rosenbrough N.J., Farr A.L., Randal R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
35. Maiese K., Chong Z.Z., Li F. Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr. Neurovasc. Res. 2005, 2:425-446.
36. Marini A.M., Ueda Y., June C.H. Intracellular survival pathways against glutamate receptor agonist excitotoxicity in cultured neurons. Intracellular calcium responses. Ann. N. Y. Acad. Sci. 1999, 890:421-437.
37. Matute C., Sanchez-Gomez M.V., Martinez-Millan L., Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8830-8835.
38. McDonald J.W., Althomsons S.P., Hyrc K.L., Choi D.W., Goldberg M.P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainite receptor mediated excitotoxicity. Nat. Med. 1998, 4:291-297.
39. Meyer R., Weisesert R., Diem R., Storch M.K., De Graaf K.L., Kramer B., Bähr M. Acute neuronal apoptosis in a rat model of multiple sclerosis. J. Neurosci. 2001, 21:6214-6220.
40. Mills C.D., Fullwood S.D., Hulsebosch C.E. Changes in metabotropic glutamate receptor expression following spinal cord injury. Exp. Neurol. 2001, 170:244-257.
41. Mitosek-Szewczyk K., Sulkowski G., Stelmasiak Z., Stróżyńska L. Expression of glutamate transporters GLT-1 and GLAST In different regions of rat brain during the course of experimental autoimmune encephalomyelitis. Neuroscience 2008, 155:45-52.
42. Ohgoh M., Hanada T., Smith T., Hashimoto T., Ueno M., Yamanishi Y., Watanabe M., Nishizawa Y. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 125:170-178.
43. Parkinson J.F., Mitrovic B., Merrill J.E. The role of nitric oxide in multiple sclerosis. J. Mol. Med. 1997, 75:174-186.
44. Paul C., Bolton C. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-d-aspartate receptor antagonist memantine. J. Pharmacol. Exp. Ther. 2002, 302:50-57.
45. Plaut G.S. Effectiveness of amantadine in reducing relapses in multiple sclerosis. J. R. Soc. Med. 1987, 80:91-93.
46. Popoli P., Pintor A., Tebano M.T., Frank C., Pepponi R., Nazzicone V., Grieco R., Pèzzola A., Reggio R., Minghetti L., De Berardinis M.A., Martire A., Potenza R.L., Domenici M.R., Massotti M. Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid-induced striatal toxicity: involvement of pre- and post-synaptic mechanisms and lack of direct NMDA blocking activity. J. Neurochem. 2004, 89:1479-1489.
47. Raine C.S., Canella B., Hauser S.L., Genain C.P. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol. 1999, 46:144-160.
48. Rose J.W., Hill K.E., Watt H.E., Carlson N.G. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J. Neuroimmunol. 2004, 149:40-49.
49. Rothwell N.J., Lubeshi G.N. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 2000, 23:618-625.
50. Salinska E., Danysz W., Lazarewicz J.W. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005, 43:322-339.
51. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
52. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1988, 23:339-346.
53. Stoll G., Jander S., Schroeter M. Cytokines in CNS disorders: neurotoxicity versus neuroprotection. J. Neural Transm. Suppl. 2000, 59:81-89.
54. Sulkowski G., Dabrowska-Bouta B., Kwiatkowska-Patzer B., Strużyńska L. Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. Folia Neuropathol. 2009, 47:327-337.
55. Sulkowski G., Dabrowska-Bouta B., Struzynska L. Modulation of neurological deficits and the expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors. Biomed. Res. Int. 2013, http://dx.doi.org/10.1155/2013/186068.
56. Takahashi J.L., Giuliani F., Power C., Imai Y., Young V.W. Interleukin-1-beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann. Neurol. 2003, 53:588-595.
57. Verkhratsky A., Kirchoff F. NMDA receptors in glia. Neuroscientist 2007, 13:28-37.
58. Villoslada P., Arrondo G., Sepulcre J., Alegre M., Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009, 72:1630-1633.
59. Volbracht C., Van Beek J., Zhu C., Blomgren K., Leist M. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur. J. Neurosci. 2006, 23:2611-2622.
60. Yoshioka A., Bacskai B., Pleasure D. Pathophysiology of oligodendroglial excitotoxicity. J. Neurosci. Res. 1996, 46:427-437.
61. Zieminska E., Lazarewicz J.W. Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studies in vitro: the role of NMDA and group I metabotropic glutamate receptors. Acta Neurobiol. Exp. 2006, 66:301-309.